MetaCap

OnKure Therapeutics Inc. Class A (OKUR)

NASDAQ: OKURHealth CareBiotechnology: Pharmaceutical PreparationsUSD

2.70-0.06 (-2.17%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

OKUR stock chart

Technical analysis

Key statistics

All statistics
Market cap
$111.21M
EPS (TTM)
-$2.26
52-week range
2.01 – 5.38
Day range
2.68 – 2.81
Volume / Avg
195.21K / 335.78K
Beta
—

52-week range

$2.01$5.38

OKUR stock today

Shares of OnKure Therapeutics (OKUR) finished lower on Nov 20 at $2.70, a drop of 2.17% or $0.06 per share, versus the S&P 500's 3.70% decline. Shares are 49.8% below their 52-week high of $5.38, set on May 1, 2026 and 34.3% above the 52-week low of $2.01, in the middle of the past year's range. OKUR is down 6.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 4.7%.

OnKure Therapeutics has posted a net loss over the last twelve months (EPS of -$2.26), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About OnKure Therapeutics

Company profile

OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Nicholas A. Saccomano Ph.D.
Headquarters
Boulder, CO
Employees
45
IPO year
2021

Financial highlights

Full financials

OnKure Therapeutics reported a net loss of $59.5 million, compared with a loss of $52.7 million a year earlier. Diluted earnings per share came in at -$4.40.

OnKure Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—$0———
Growth—————
Net income$-59.52M$-52.67M$-35.31M$-51.95M$-39.77M
EPS (diluted)$-4.40$-15.28$-124.41$-2.12$-2.19

Analyst forecast

Forecast

Consensus (6 analysts)

none

Avg. price target

$15.25+464.81%

  • Strong buy 0
  • Buy 5
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $11.00High $21.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.36 vs $-0.29
Surprise
-24.14%

OKUR news

All OKUR news

OnKure Therapeutics peers

Health Care sector
OKUR peer companies
CompanyPrice% ChgMarket capCompare
IMUXImmunic Inc.6.99-5.41%$111.01Mvs OKUR
MENSJyong Biotech Ltd.1.45-17.14%$110.24Mvs OKUR
SPRBSpruce Biosciences Inc.38.00-6.15%$109.21Mvs OKUR
BGMBGM Group Ltd. Class A8.130.00%$108.57Mvs OKUR
AKBAAkebia Therapeutics Inc.0.3855-8.71%$107.04Mvs OKUR
ADAGAdagene Inc. ADR1.76-12.44%$118.17Mvs OKUR
GNLXGenelux Corporation2.17-4.82%$103.36Mvs OKUR
FHTXFoghorn Therapeutics Inc.1.72-3.37%$103.14Mvs OKUR

Indexes, lists and sector

OnKure Therapeutics stock FAQ

What is OnKure Therapeutics's stock price today?

OKUR last traded at $2.70 as of Nov 20, 4:00 PM EST, down 2.17% on the day. Prices are delayed at least 15 minutes.

Does OnKure Therapeutics pay a dividend?

No. OnKure Therapeutics does not currently pay a regular cash dividend.

Who is OnKure Therapeutics's CEO?

Dr. Nicholas A. Saccomano Ph.D. is the chief executive officer of OnKure Therapeutics Inc. Class A, which has about 45 employees.

Has OKUR ever split its stock?

Yes. The most recent OKUR stock split was a 1-for-10 split on Oct 7, 2024.

What is the OKUR 52-week high?

The 52-week high for OKUR is $5.38 and the 52-week low is $2.01. The stock is currently 49.8% below its high.

Compare OKUR